Multigene prognostic assay for lung cancer
AssigneeThe Regents of the University of California
InventorsDavid M. JABLONS, Dan J. RAZ, Biao HE
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma.
Claims21
A method of providing a prognosis for lung cancer in a subject, the method comprising the steps of:
- (a) contacting a biological sample from the subject with reagents that each specifically bind to one member of a panel of biomarkers comprising ctnnb1, wnt3a, tp53, has, erbb3, muc1, erbb2, and dusp6, and
- (b) determining whether or not the markers are differentially expressed in the sample;
- thereby providing a prognosis for lung cancer.
A kit comprising reagents that each specifically bind to one member of a panel of biomarkers comprising ctnnb1, wnt3a, tp53, kras, erbb3, muc1, erbb2, and dusp.
A method of providing a prognosis of a subject having a lung cancer method comprising quantifying in a biological sample the expression levels of at least two biomarkers selected from a group consisting of:
- rnd3, wnt3a, erbb3, lck, sh3bgr, fut3, il11, cdc6, cdk2ap1, bag1, emx2, six3, and brca1 ;
- wherein said biological sample is derived from said subject and said expression levels are indicative of said prognosis.
21-49. (canceled)
Dependencies are inferred from the claim text.